Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 139481-59-7
Drug Levels and Effects
Summary of Use during Lactation
Preliminary evidence suggests that candesartan passes poorly into milk and is barely detectable in the plasma of breastfed infants. Use of candesartan is not a reason to discontinue nursing, but use caution in newborn and preterm infants.
Drug Levels
Maternal Levels. Three women taking candesartan for at least 2 weeks donated several milk samples, either as fore-and hindmilk samples or as a total milk collection at each time, over a 24-hour period after taking a dose of the drug. Two women were taking 8 mg daily and one was taking 32 mg daily. The peak milk level was 3.78 mcg/L with the 32 mg dose and 0.69 and 1.05 mcg/L with the 8 mg doses. Peak milk times were about 7.75, 8, and 9.25 hours after the dose. The authors estimated that the infant would receive a weight-adjusted maternal dosage between 0.8 and 1%.[1]
Infant Levels. Two infants aged 8 and 13 months were breasted (extent not stated) by mothers taking candesartan 8 mg daily. Blood samples were taken at about 2.5 and 3.5 hours after the maternal doses (time of nursing not reported). Plasma candesartan concentrations were less than 0.2 mcg/L in both infants.[1]
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
References
- 1.
- Coberger ED, Jensen BP, Dalrymple JM. Transfer of candesartan into human breast milk. Obstet Gynecol. 2019;134:481–4. [PubMed: 31403599]
Substance Identification
Substance Name
Candesartan
CAS Registry Number
139481-59-7
Drug Class
Breast Feeding
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Blockers
ARBs
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Review Valsartan.[Drugs and Lactation Database (...]Review Valsartan.. Drugs and Lactation Database (LactMed®). 2006
- Review Olmesartan.[Drugs and Lactation Database (...]Review Olmesartan.. Drugs and Lactation Database (LactMed®). 2006
- Review Irbesartan.[Drugs and Lactation Database (...]Review Irbesartan.. Drugs and Lactation Database (LactMed®). 2006
- Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).[J Pharmacol Exp Ther. 1993]Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).Shibouta Y, Inada Y, Ojima M, Wada T, Noda M, Sanada T, Kubo K, Kohara Y, Naka T, Nishikawa K. J Pharmacol Exp Ther. 1993 Jul; 266(1):114-20.
- Review Azilsartan.[Drugs and Lactation Database (...]Review Azilsartan.. Drugs and Lactation Database (LactMed®). 2006
- Candesartan - Drugs and Lactation Database (LactMed®)Candesartan - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...